About 70% of evening news television advertisements are for direct-to-consumer monoclonal antibody therapies for autoimmune or hyperimmune conditions.
"If you don't think that's the case, watch the evening news and see what about 70% of the advertisements are for: they're for monoclonal antibody-based direct-to-consumer drug platforms to get you to ask your doctor about this monoclonal antibody for this particular hyper/autoimmune immune condition." (said at 0:47:48)
No published record matching the claim that approximately 70% of evening news television advertisements are for direct-to-consumer monoclonal antibody therapies for autoimmune or hyperimmune conditions was located; this does not prove the claim false. While pharmaceutical direct-to-consumer advertising is common during broadcast television news programming, no empirical content analysis or media monitoring study in the published literature documents this specific proportion for monoclonal antibody therapies targeting autoimmune diseases.
Industry advertising tracking and news media analyses report that all pharmaceutical advertisements combined account for roughly 24% to 30% of ad time during network evening newscasts. Monoclonal antibody therapies for autoimmune conditions represent only a fraction of those pharmaceutical commercials, alongside treatments for diabetes, cardiovascular disease, weight management, and other conditions.